CD86 and neoplasm: Not surprisingly, the CD86 to CD206 ratio on tumor-associated macrophages and myeloid-derived suppressor cells [i.e. often considered a measure of M1:M2 ratio (32, 39)] also increased (Figure 5C), further suggesting that the targeted reprogramming of Tregs also impacts tumor-infiltrating myeloid cells.